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OBJECTIVES: To evaluate the feasibility and cost of conducting home-based med-
ication reviews (HBMR) among community-dwelling multi-ethnic Singaporeans
and permanent residents.METHODS: In this cross-sectional study, Chinese, Malay
and Indian aged 40 and over and on at least 5 medications were referred by their
general practitioners (GPs) for HBMR. Patients completed a survey on sociodemo-
graphic and clinical information. Pharmacists’ time spent on HBMR and preparing
visit reports were captured and assigned a cost based on pharmacists’ average
hourly wages. Drug related problems (DRP) were evaluated using the Westerlund
DRP classification system, reported to and followed up with the GPs. RESULTS: Of
14 participants referred, 9 consented (64.3%; 6 women; 6 Chinese, 2 Malays, 1 In-
dian; mean (SD, range) age: 69.3 (10.6, 52 – 86 years). Seven out of the 9 patient were
under the care of at least two physicians. Dyslipidemia, hypertension and diabetes
are themain condition affecting the participants (100%, 88.9%, 66.7%, respectively).
A total of 12 DRP were detected: underuse of medication (n7, of which 2 were due
to non-compliance), overuse of medication (n1), incorrect timing (n2) and ther-
apy failure (n2). Pharmacists spent an average 3.5 hours per home visit. Total
programme cost was $787.5 (9 visits x $25/hr x 3.5hr/ visit). Hence, cost per DRP
detected was estimated at $65.63. One of the DRP detected was vertigo without
treatment. Hence, programme cost may be potentially offset by the savings from
avoiding an episode of hospitalization due to fall. CONCLUSIONS: DRP is prevalent
and potentially preventable but were undetected in this primary care sample.
Hence, there is a role for HBMR. We are currently conducting a longitudinal ran-
domized controlled trial to evaluate the cost-effectiveness of providing and not
providing HBMR by collecting direct and indirect costs, health services utilization
and health-related quality of life outcomes at baseline and 6-months.
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OBJECTIVES: Pharmacists have a remarkable role in rational use of drug by presen-
tation of drug information as patient educator, explanation, assessment and per-
formance of drug orders, contribution in drug selection and utilization as physician
consultant, drug utilization review and participation in patient outcomes in am-
bulatory settings.The aim of this study is to evaluate pharmacists’ opinion about
the factors affecting rational drug use. METHODS: In a cross sectional survey,
questionnaires of the study were completed in Convenient Sampling by pharma-
cists who had been attended in rational use of drug congress in Tehran. RESULTS:
A total of 147 pharmacists were enrolled to the study and the highest priorities in
irrational use of drug by pharmacists were revealed including 39% lack of appro-
priate cooperation and communication between physicians and pharmacists, 34%
pharmacists’ low tariff and economic issues, 45% lack of public knowledge about
drug use and 15.8% lack of regulations. CONCLUSIONS: Lack of public knowledge
and awareness about appropriate use of medicines was found the most important
factor in promoting irrationality in drug use. Dissemination of rational use of drug
ideas, compiling of diverse strategies in education, management, regulation and
finance can be very efficient due to a strong relationship between drug policies and
performance of regulations and supervisions as well as drug services methods.
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OBJECTIVES: To evaluate the 3-year National Health Insurance reimbursements
among atrial fibrillation (AF) patients with and without stroke in one year in
Taiwan.METHODS: The data were retrieved from the Taiwan Longitudinal Health
Insurance Database, which consists 1,000,000 Taiwanese people’s claimed data
from 2005 to 2008. The study cohort consisted of 17,427 patients with newly diag-
nosed AF in 2005 and 537 occurred stroke in 2006. Each patient was individually
followed-up for 3 years period from 2006 to 2008. The generalized linear model
(GLZM) was used to estimate the health care reimbursements and the risk to hos-
pitalize among AF patients. RESULTS: The estimated incidence rate of atrial fibril-
lation was 1.74% per person year. Besides, among AF patients, the estimated inci-
dence of stroke was 3.08% per person year. After adjusting for age and sex, AF
patients with stroke had statistically significant higher outpatient reimbursement
(NTD$44, 941 vs 38,078/person-year) and inpatient reimbursement (NTD$ 1,630,222
vs. 960,702/person-year) than AF patients without stroke. Also, the results of GLZM
revealed a statistically significant hazard ratio to be hospitalized in AF patients
with stroke (HR1.93; 95% CI1.73-2.15, p-value0.001). AF patients with stroke,
however, did not have statistically significant difference of annual outpatient visits
from AF patients without stroke (33 vs 32 times/person-year). CONCLUSIONS: This
study demonstrated that AF patients with strokewere found to utilize significantly
more national health insurance reimbursements than AF-alone patients and also
to be at a significant higher risk of hospitalization during a 3-year follow-up period
after diagnosis.
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OBJECTIVES: Pay-for-Performance (P4P) programwas introduced in Taiwan in 2001
for treatment of breast cancer (BC), diabetes mellitus (DM), tuberculosis (TB),
asthma, and cervical cancer. Although P4P is increasingly being implemented,
there remains insufficient evidence to support the belief that the P4P incentive
design improved the outcomes of care.METHODS: Embase® and MEDLINE® were
searched from 2001-2012 using the key terms pay-for-performance and P4P for
studies published in English. RESULTS: Of the 1413 screened, 14 studies assessing
P4P program in Taiwan were identified. Studies assessing P4P in patients with
asthma and cervical cancerwere not retrieved. The BC-P4P enrolees received better
quality care (p0.001), resulting in better 5-year overall survival (odds ratio [OR]:
5.99; p0.003) and less recurrence (OR: 2.70; p0.002) when compared to non-
enrolees. The effect was more pronounced in low-volume hospitals (OR: 1.38;
[95%CI: 1.08 - 1.77]) and non-medical centres (OR: 1.62; [95%CI: 1.24 - 2.11]). Among
TB-P4P enrolees, cure rate within 12 months of treatment significantly increased
(OR, 1.338; [95%CI: 1.159 - 1.544]), whereas default rate from treatment significantly
decreased (OR, 0.904; [95%CI: 0.702 - 0.973]) compared to non-P4P enrolees. In DM-
P4P enrolees, the cost of diabetes-related physician visits was higher (5731 NT$/
patient), however, costs of diabetes-related hospitalisations (-5099 NT$/patient)
and overall expenditures on health services (-10 543 NT$/patient) were consider-
ably lower compared to non-enrolees. Hospitals in cities with low-income levels
were more likely to participate in P4P programs compared to hospitals in high-
income level cities (OR: 4.53; [95%CI: 2.87 - 7.16]). The results illustrated that older
patients and patients with high co-morbidity/severity were prone to be excluded
from P4P programs. CONCLUSIONS: Patients enrolled in the P4P program received
a better quality of care and demonstrated better outcomes than the non-enrolled
patients. However, benefit of P4P can be extended by including older patients and
those with higher disease severity and co-morbidities.
PHP74
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OBJECTIVES: The Drug Benefit Committee (DBC) appraises the value of new drug
and categorises it as class 1 (substantial improvement), 2A (moderate improve-
ment) or 2B (similar) according to relative treatment effect of new drug compared
with the exiting treatment(s), and pricing method link to the category is decided.
When DBC considers more information is required the application will be further
discussed in extension meeting, and appeal could be entered if the license holder
did not agree upon the result. We analyzed the features of new drug applications
and corresponding DBCmeeting outcomes in 2007 and 2008.METHODS:Data were
abstracted from the applications and DBC meeting minute. RESULTS: There were
82 applications during the study period, 51 were submitted by the multinational
companies and 31 by domestic companies; 6 applied for class 1; and 70were single-
compound. By end of 2008, 63 (77%) were reimbursed; for the unreimbursed, 7 were
withdrawn by the applicants and 12were denied by theDBC. 20 newdrugs received
unconditional recommendation, 43 with conditional coverage. 31 (38%) submis-
sions entered appeals, 22 for price and 9 for reimbursement decision. Appealed
successfully in 22 (71%), but double the duration to reach final result. The final
reimbursed prices were 81% to 91% of the applied price in class 1, and 55% to 73% in
class 2. The feature of company (foreign or domestic) and the ratio of applied to the
first DBC decided price had influence on the decision of company to enter an
appeal. CONCLUSIONS: The reimbursement and price process is evolving contin-
uously. How to justify the value of treatment to the community, scientific sound
methods for assessment and appraisal, and transparency of the process and out-
comes are the important considerations. The cumulative experience is valuable for
future improvement.
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OBJECTIVES: Due to high unmet needs and low prevalence, orphan drugs can be
approved by regulatory authorities based on evidence demonstrated through sin-
gle-arm study designs; indeed, randomized studies in rare diseases may not be
feasible. As part of a health technology assessment (HTA) evidence package, how-
ever, value demonstration through comparison to existing therapies or supportive
care is always required. This study aimed to explore the value perceived by reim-
bursement authorities for an orphan therapy in a single-arm trial evidence pack-
age, and to understand any supplementary evidence requirements for value
demonstration. METHODS: Fourteen experts in HTA, pricing and reimbursement
(P&R) decison makers, and influencers in China, South Korea, Taiwan, and Thai-
land were recruited and interviewed, following a comprehensive discussion guide.
The responses were further analysed to identify the key challenges in value dem-
onstration and what clinical and economic evidence the respondents found ac-
ceptable in evaluating orphan drugs. RESULTS: In all countries, payers valued in-
novative therapies for rare diseases and were understanding towards limitations
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